Drug intelligence / Profile preview

levonorgestrel + metformin

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral, Intrauterine

Overview

A combination therapy consisting of levonorgestrel (a synthetic progestogen commonly used in contraceptives) and metformin (an insulin-sensitizing drug). This combination is being studied for the treatment of endometrial intraepithelial neoplasia (EIN), endometrial cancer (EC), and polycystic ovary syndrome (PCOS). For endometrial conditions, it is typically administered as a levonorgestrel-releasing intrauterine device (LNG-IUD) plus oral metformin, while for PCOS it may be given as oral contraceptive pills containing levonorgestrel plus oral metformin.

Targets

AMPK (Adenosine monophosphate–activated protein kinase)PR (Progesterone receptor)

Beyond the preview

Go deeper on levonorgestrel + metformin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on levonorgestrel + metformin.

Explore the full profile